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Tick chemokine-binding proteins (evasins) are an emerging
class of biologicals that target multiple chemokines and show
anti-inflammatory activities in preclinical disease models.
Using yeast surface display, we identified a CCL8-binding eva-
sin, P672, from the tickRhipicephalus pulchellus.We found that
P672 binds CCL8 and eight other CC-class chemokines with a
Kd< 10 nM and four other CC chemokines with aKd between 10
and 100 nM and neutralizes CCL3, CCL3L1, and CCL8 with an
IC50< 10 nM. The CC chemokine–binding profile was distinct
from that of evasin 1 (EVA1), which does not bind CCL8. We
also show that P672’s binding activity can be markedly modu-
lated by the location of a StrepII-His purification tag. Combin-
ing native MS and bottom-up proteomics, we further demon-
strated that P672 is glycosylated and forms a 1:1 complex with
CCL8, disrupting CCL8 homodimerization. Homology model-
ing of P672 using the crystal structure of the EVA1 and CCL3
complex as template suggested that 44 N-terminal residues of
P672 form most of the contacts with CCL8. Replacing the 29
N-terminal residues of EVA1with the 44N-terminal residues of
P672 enabled this hybrid evasin to bind and neutralize CCL8,
indicating that the CCL8-binding properties of P672 reside, in
part, in its N-terminal residues. This study shows that the func-
tion of certain tick evasins can bemanipulated simply by adding
a tag. We conclude that homology modeling helps identify
regionswith transportable chemokine-binding functionswithin
evasins, which can be used to construct hybrid evasins with
altered properties.
Chemokines are a family of secreted proteins that are major
drivers of both physiological andpathological inflammation (1).
They fall into four groups, CC, CXC, XC, and CX3C, which are
defined by the spacing between their N-terminal cysteine re-
sidues (2). Structural features common to all chemokines
include: a flexible N terminus followed by the double cysteine
motif, the N-loop, a helix, a three-stranded sheet with 30S
(between 1 and 2) and 40S (between 2 and 3) loops, and
a C-terminal helix. The distal N terminus of the chemokine
binds to the chemokine recognition site 2 (CRS2)6 pocket of
G-protein–coupled chemokine receptors, whereas the proxi-
mal N terminus and N-loop/40S loop grooves bind chemokine
recognition site 1 (CRS1) in the extracellular N terminus of the
receptor (3, 4). Binding to the CRS2 pocket results in confor-
mational changes in the G-protein–coupled receptor that acti-
vates signaling. Binding of chemokines to target receptors is
typically a “one-to-many” interaction, with several chemokines
binding more than one receptor and several receptors binding
more than one chemokine. Chemokines also bind with low
affinity to endothelial cell surface glycosaminoglycans, which is
necessary for chemokine function in vivo (5). The 19 chemo-
kine receptors that activate chemotaxis are expressed in varying
combinations on adaptive and innate immune cells, and activa-
tion by chemokines promotes their directional migration to
sites of chemokine expression (6–8). The one-to-many inter-
actions between chemokines and receptors, the expression of
multiple receptor types on immune and inflammatory cells, and
the expression of multiple chemokines at the site of injury or
diseased tissues leads to the creation of a robust network that is
not amenable to traditional therapeutics thatmonovalently tar-
get either chemokines or their receptors.
Natural selection in viruses, helminths, and ticks has resulted
in the convergent evolution of proteins that target the chemo-
kine network by different mechanisms (reviewed in Refs. 9 and
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10). For instance, the viral proteins MC148 and vMIP-II bind
and inhibit multiple chemokine receptors. Other viruses have
evolved chemokine-binding proteins (CKBPs) that bind multi-
ple CC and CXC chemokines and disrupt glycosaminoglycan
binding or disrupt chemokine binding to the receptor or both
(11). Helminth CKBP also binds multiple CC and CXC chemo-
kines, but the mechanism of action is not clearly understood
(12). Ticks, uniquely, have two classes of CKBPs, called evasins,
with one class typically containing eight conservedCys residues
(“8-Cys” tick CKBPs) that bind subsets of CC chemokines and
another class containing six conserved Cys residues (“6-Cys”
CKBPs) that bind CXC chemokines. Following the initial iden-
tification of class I tick CKBPs, exemplified by evasin 1 (EVA1_
RHISA, abbreviated toEVA1) andevasin4 (EVA4_RHISA, abbre-
viated to EVA4), and a class II CKBP, exemplified by evasin 3
(EVA3_RHISA (13), abbreviated to EVA3), we (14) and oth-
ers (15) have identified several other examples of CC-CKBPs
from diverse tick species. The structure of EVA1 in complex
with CCL3 shows that it has 1:1 stoichiometry, with the N
and C termini of EVA1 binding the N terminus andN-loop of
CCL3 (16). The selectivity of the EVA1–CCL3 interaction
resides in the six residues that immediately precede the dou-
ble cysteine motif in CCL3. Binding results in a conforma-
tional change of the N terminus of CCL3, and this, together
with the binding of the N-loop, explains the inhibition of
chemokine activity (16). In silico modeling and mutagenesis
studies indicate that EVA4 also targets the CCL3 N terminus
(17). Both EVA1 and EVA4 have been shown to have anti-
inflammatory efficacy in several preclinical disease models,
suggesting that they may be potential therapeutics in inflam-
matory disease (13).
Using yeast surface display, we have isolated a novel CCL8-
binding CKBP from the tick Rhipicephalus pulchellus called
P672_RHIPU (abbreviated to P672). We show that P672 binds
and neutralizes several CC chemokines and that its ability to
bind and neutralize chemokines ismodulated by the location of
a purification tag. We show that binding to CCL8 occurs with
1:1 stoichiometry and disrupts CCL8 homodimer formation.
Using molecular modeling we identified a CCL8-binding
region in P672 that can be transplanted to EVA1, a protein that
does not bind CCL8. These results show that tick CKBP func-
tion can be modulated in some cases by the addition of a tag,
providing proof of the concept that regions within tick CC-
CKBPs with transportable properties can be identified and
manipulated to create non-natural hybrid proteins with altered
characteristics.
Results
Screening of a yeast surface display library
Weused fluorescence-activated cell sorting (FACS) to screen
a yeast surface display library as described in detail previously
(14). The plasmid library was constructed to express 352 puta-
tive tick CKBPs with either N-terminal (AGA2) or C-terminal
(SAG1 or AGA2) surface display tags. The plasmid library was
transformed as a pool into yeast, and the cells were labeled with
biotinylated CCL8 and streptavidin-AF647. The labeled cells
were sorted by two rounds of FACS (Fig. 1, A and B). In each
round, we used a sorting gate determined by FACS analysis of
the yeast cells with streptavidin-AF647 alone. The sorting gate
was used to exclude yeast cells displaying background fluores-
cence generated by streptavidin-AF647 binding to yeast. Cells
that were recovered in the first sort were regrown and then
sorted once again (Fig. 1C). Cells recovered in the second sort
were next plated at low density, and individual yeast clones
were picked and retested by labeling them with biotinylated
CCL8 and streptavidin–Alexa Fluor 647. The clones picked
were compared with control yeast expressing the relevant sur-
face display tag (Fig. 1D). In these experiments, we found that
only a proportion (30.8%) of the clonal yeast population would
bind CCL8. Two independent clones recovered in this screen
encoded a novel tick CKBP, P672 (GenBankTM accession num-
ber JAA60789.1). Both clones were obtained with an N-termi-
nal surface display tag.
Sequence analysis of P672
P672 has 104 amino acid residues with a predictedmolecular
mass of 11.7 kDa and a predicted isoelectric point (pI) of 4.45.
The glycosylation site prediction indicates several N-glyco-
sylations and a single O-glycosylation site. Protein sequence
alignment with EVA1, EVA4, and other CC-CKBPs identi-
fied by yeast surface display shows that P672 retains the
eight Cys residues that form disulfide bonds in EVA1. The
arrangement of the Cys residues is consistent with the motif
CX(14,17)CX(3)CX(11,16)CX(17,20)CX(4)CX(4)CX(8)C that
we have described previously (14) (Fig. 2A). Phylogenetic anal-
ysis of the protein sequence shows that P672 is most closely
related to EVA4 (Fig. 2B), withwhich it shares 36% identity over
an alignment length of 105 residues. It shares only 29% identity
with EVA1, over an alignment length of 89 residues. There is no
significant homology to EVA3. The Pro residue in EVA1 that
immediately follows the firstCys residue and contacts the disul-
fide bond inCCL3 (18) is replaced by aTyr residue, as is the case
for EVA4. The conservation plot (Fig. 2C) shows that the N and
C termini of CC-CKBPs are less well conserved than the central
core region.
Expression and purification of P672
We expressed P672 as a secreted protein from mammalian
cells essentially as described previously (14). We purified P672
with a C-terminal StrepII-His purification tag by nickel affinity
followed by size exclusion chromatography. However, as P672
was obtained only in an N-terminally tagged orientation in the
yeast surface display screen, we also used an N-terminal His-
StrepII tag approach to purify the protein. The purified protein
in each case migrated at a larger molecular mass than expected
(Fig. 3 and Fig. S1). This is consistent with its predicted glyco-
sylation, which was confirmed by digestion of the protein with
the glycosidases PNGaseF and Endo F1. On digestion, the
smeared band collapses to a single band close to the predicted
molecular mass on SDS-PAGE (Fig. 3) together with a corre-
sponding change in retention volume on size exclusion chro-
matography (Fig. S1A).
Hybrid evasins
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Tandemmass spectrometry identification of glycosylated sites
in P672
Tandemmass spectrometry (MS/MS) analysis at the peptide
level of P672 treated with PNGaseF and Endo F1 was per-
formed, and we were able to achieve sequence coverage of 87%,
excepting the residues indicated in Fig. 2A. This identified sev-
eral deamidated residues that had converted from Asn to Asp,
corresponding to a mass shift of 0.98 Da in NX(S/T) motifs
(supplemental material Table S1). Deamidation of Asn is a
characteristic feature of N-glycosylation cleavage by PNGaseF
(19) and indicates that the Asn residues are N-glycosylated.
Only partial deglycosylation by PNGaseF and Endo F1 was
achieved as supported by the finding of several peptides in
deamidated and glycosylated forms carrying N-acetylgluco-
samine and/orN-acetylgalactosamine (HexNAc)moieties. The
presence of HexNAc can be explained by the Endo F1 cleavage.
TheN-glycosylation sites identified byMS/MS are indicated in
Fig. 2A.
Binding of P672 to chemokines
We next explored the binding profile of glycosylated P672,
with both theN- andC-terminally tagged forms to a chemokine
panel using biolayer interferometry (20). CKBPs were immobi-
lized on the sensor through their His tag, and initial screening
assays performed at 300 nM chemokine concentration indi-
cated that P672 boundonly certainCCchemokines.Nobinding
was detected to CXC, XC, or CX3C chemokines (data not
shown). Binding affinities (Kd) were subsequently determined
through biolayer interferometry titration studies against these
CC chemokines (Fig. 4). Notably, we observed different binding
patterns when P672 was tagged at the C terminus, specifically
the loss of binding to CCL14, CCL15, CCL11, CCL7, CCL2,
CCL13, CCL1, andCCL16 at 300 nM chemokine concentration.
We also noted a marked variation in target residence time (cal-
culated from the off-rate) with P672 tag positioning, e.g. for its
binding to CCL8.
Neutralization of chemokines by P672
We next explored the ability of P672, in N- and C-terminally
tagged versions, to inhibit chemokine function. We monitored
their effects on the migration of THP-1 human monocyte cells
in response to humanCCchemokines in 96-well Boyden cham-
ber assays (Fig. 5). We determined the effect of titrating in pro-
gressively increasing doses of P672 at the effective concentra-
Figure 1. Yeast surface display screen. A, fluorescence profile of yeast surface display library expressing putative tick evasins incubated with streptavidin-
AF647 alone. The red outlined box indicates the sorting gate. B, yeast surface display library incubated with biotinylated CCL8 plus streptavidin-AF647. The
sorting gatewas identified from the negative control andwas used to sort CCL8-binding yeast from the library. C, second round sorting of CCL8-binding yeast
identified above. The proportions of cells within the sorting gate are indicated as a percentage. D, binding of P672 to CCL8. Yeast expressing P672 are shown
in red, and control yeast bearing empty vector surface display plasmid are shown in blue. The y axis shows cell count and x axis the fluorescence intensity on a
log10 scale. The proportion of cells exceeding background is indicated as a percentage.
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tion (EC) dose, EC80, for each CC chemokine and found that
N-terminally tagged P672 inhibits THP-1 cell migration in
response to CC chemokines with IC5010 nM (Fig. 5,A–C). The
relative effects of tag position were determined by comparing the
ability of the N- or C-terminally tagged form of P672 to inhibit
THP-1 cell migration (Fig. 5D). The C-terminal tag position had
marked effects on the ability of P672 to inhibit CCL2- and CCL7-
activated chemotaxis. Tag positionhadno significant effect on the
ability of P672 to inhibitCCL3,CCL3L1, orCCL8 function.This is
consistent with the binding data presented above and indicates
that tag position can affect not only the binding of P672 to chemo-
kines but also its function in solution.
Characterization of P672 in complex with CCL8
To understand the mechanism of P672 binding to CCL8, we
characterized individual proteins and the complex using native
mass spectrometry. As glycosylation can affect native mass
Figure 2. Analysis of P672 protein sequence. A, sequence alignment of P672 with CC-binding evasins. The peptide sequence prefix indicates the identity,
and suffixes indicate the tick species as follows: RHISA and RHIPU, Rhipicephalus sanguineus and R. pulchellus, respectively; AMBPA, AMBCA, AMBMA, and
AMBTR, Amblyomma parvum, Amblyomma cajennense, Amblyomma maculatum, and Amblyomma triste, respectively. Amino acid residues are color-coded
according to physicochemical properties: yellow, aromatic (F,W, and Y); red, acidic (D and E); blue, basic (R, H, and K); orange, nonpolar aliphatic (A, G, I, L,M, P,
and V); green, polar neutral (C,N,Q, and T). The green arrows indicate disulfide bond positions in EVA1.Magenta arrows indicate the sixN-glycosylated residues
identified in P672 bymass spectrometry. The blue lines indicate the regions of P672 not covered by elastase and tryptic digest bottom-upmass spectrometry.
Sequence rulers of P672, EVA1, and the alignment (ruler 1) are indicated. B, phylogenetic tree of CC-binding evasins. P672 is relatedmost closely to EVA4, with
which it shares 36% identity over 105 residues. C, conservation plot of evasins identified by yeast surface display. The plot was generated from the sequence
alignment using the EMBOSSprogramPlotconwith awindowsize of 10 residues. The y axis shows the similarity score, and the x axis shows the residueposition
in the alignment.
Figure 3. Analysis of glycosylated and deglycosylated P672 by SDS-
PAGE. The gel is stained with colloidal Coomassie Blue. Shown are molec-
ular mass markers (kDa, lane 1), N-terminally tagged P672 protein (lane 2),
C-terminally tagged P672 protein (lane 3), and N-terminally tagged P672
protein (lane 4), partially deglycosylated using PNGaseF and EndoF1. All
proteins were purified using nickel affinity followed by size exclusion
chromatography.
Hybrid evasins
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spectrometry unpredictably, we used partially deglycosylated
P672 for these experiments. The affinity of partially deglycosy-
lated N-terminally tagged P672 for CCL8 was 7.25E-8 M (Fig.
S1B), indicating that native mass spectrometry of the P672-
CCL8 complex would be feasible and would allow us to eluci-
date the stoichiometry of the interaction.
Initially, CCL8 and P672 were characterized separately.
CCL8 was expressed bacterially as an N-terminal His-SUMO
fusion, which following SUMO cleavage produced a newN ter-
minus corresponding to glutamine (Gln-24). The presence of
the glutamine N-terminal residue was confirmed using high
resolution native MS/MS. The N-terminal glutamine of CCL8
can cyclize to form pyroglutamic acid, which is required for
CCL8 biological activity (21). During electrospray ionization
the N-terminal glutamine can also readily cyclize to form pyro-
glutamic acid. This change corresponded to the most intense
peak observed, and the identity and site of modification were
supported by higher-energy collision dissociation (HCD) frag-
ment ions (Fig. S2). Purified CCL8 was biologically active in a
cell migration assay (data not shown). We found that CCL8
formed a homodimer under native mass spectrometric condi-
tions with an averagemass of 22,566.6 0.8 Da (Fig. 6A). In the
case of P672 treated with PNGaseF and Endo F1, native MS
spectra were more complex due to the presence of partial gly-
cosylations, deamidations, and sodium adducts (Fig. 6B). The
average masses observed ranged from 14,588 to 16,628 Da
depending on the modifications present. Moreover, mass dif-
ferences of203 Da were observed, suggesting the presence of
HexNAc moieties, which supports the results obtained by bot-
tom-up proteomics (Fig. S3).
Native mass spectrometry of the CCL8-P672 complex
(mixed in at a 1:1 ratio) showed peaks of averagemasses ranging
from 25.9 to 27.9 kDa, which corresponds well with that
expected for a glycosylated and sodiated CCL8-P672 het-
erodimer (Fig. 6C, top panel). To demonstrate that this was the
CCL8-P672 complex, them/z 2956 was isolated with a 100m/z
isolation window and fragmented with HCD at 100 V. We
observed that the complex clearly dissociated into CCL8 and a
Figure 4. Characterization of P672 binding to chemokines using biolayer interferometry. A, binding affinities (Kd, M) and target residence times (RT,
minutes) of immobilized P672 (either N- or C-terminally tagged as indicated) to human CC-chemokines using biolayer interferometry. High-affinity binding
and longer residence times are indicated as shades of green, medium affinity as yellow, and low affinity as shades of orange. Chemokines are arranged by
sequence similarity–based phylogeny. A dash (—) indicates that binding was not detected at 300 nM chemokine concentration. B, biolayer interferometry
sensorgrams showing C-terminally tagged P672 binding to different doses of chemokines CCL3 (top panel) and CCL8 (bottompanel). Plots displaywavelength
shift (y axis, nm) versus time (x axis, seconds). Solid lines indicate collected data, and dashed lines indicate fitted data. C, biolayer interferometry sensorgrams
showing N-terminally tagged P672 binding to different doses of chemokines CCL3 (top panel) and CCL8 (bottom panel). Plots display wavelength shift (y axis,
nm) versus time (x axis, seconds). Solid lines indicate collected data, and dashed lines indicate fitted data.
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partially glycosylated P672 (Fig. 6C, bottom panel). To further
explore complex formation, we performed native mass spec-
trometry of the P672-CCL8 complex with increasing amounts
of CCL8 (Fig. S4). At a 1:1 and 2:1 ratios of CCL8:P672, we
observed three peaks corresponding to 1:1 heterodimers. At a
3:1 ratio of CCL8:P672, the 1:1 heterodimeric complex contin-
ued to be observed along with monomeric and homodimeric
CCL8 species. This confirms the 1:1 complex of P672 with
CCL8 and indicates that CCL8 homodimers are disrupted by
P672.
Homologymodeling of P672 in complex with CCL8
The published structure of the EVA1-CCL3 complex (Pro-
tein Data Bank ID 3FPU) also has 1:1 stoichiometry (16), and
this template allowed the modeling of the P672-CCL8 complex
using the program MODELLER (22) (Fig. 7). The model sug-
gested that the conservedCys residues in P672 formed disulfide
bonds in amanner similar to EVA1.We next used the Arpeggio
(23) Web server to identify interchain interactions and the
binding surface on P672. The model suggested that key CCL8-
interacting residues were present in theN terminus of P672, i.e.
residues Glu-17—Asn-44. Themodel does not provide any role
for the extended N terminus of P672 (i.e. residues Val-1—Thr-
16), which do not align to EVA1 (Fig. 2A). Truncation of resi-
dues Val-1—Thr-16 in P672 resulted in a modest decrease in
binding affinity to CCL8 (Kd  30.4 nM) suggesting that these
residues may contribute to binding (Fig. S5). The model also
shows that part of the binding surface (residue Asn-34) is
adjacent to the C-terminal residue of P672 in the 3D struc-
ture (Fig. 7).
Characterization of P672-EVA1 hybridmolecules
The homology model constructed above suggested that the
N-terminal residues of P672 may represent a region that con-
fers binding to CCL8. To evaluate this hypothesis, we took
advantage of the fact the EVA1 does not bind CCL8. The align-
ment of EVA1 with P672 (Fig. 2A) indicated that the predicted
CCL8-binding residues are proximal to the second conserved
Cys in P672. We replaced the N-terminal 29 residues of EVA1
with the equivalent N-terminal 44 residues of P672. This con-
struct maximized the predicted CCL8 binding interface. We
also created other, more extended hybrid molecules, replacing
longer regions of EVA1 with the equivalent residues of P672
(Fig. 8A). These proteins were tagged at the C terminus with a
StrepII-His tag so that changes (e.g. deletions) at theN terminus
of P672 could be made without creating steric effects. We also
constructed an identically tagged version of EVA1. We
expressed these proteins as described above (Fig. S6) and char-
acterized them for binding to target chemokines by biolayer
interferometry. We initially assessed all CKBPs for binding at
300 nM chemokine concentration and then performed titration
experiments to determine Kd (Fig. 8B). EVA1 bound to the
closely related chemokines CCL4L1, CCL4, CCL3L, CCL3,
CCL18, and CCL14. No binding was detected to other CC
chemokines, consistent with previously reported results (16).
Binding to CCL3, CCL3L1, and CCL23 was lost in all the
hybrids. All hybrid CKBPs bound CCL8 and CCL18. We next
tested for whether the P672 (1_44)-EVA1(29_94) hybrid would
neutralize CCL8 function, and we found that it did so with a
mean IC50 of 48 nM (Fig. 8C). As wildtype EVA1 does not bind
CCL8, these results indicate that the N-terminal 44 residues of
P672, which represent 42% of the P672 protein, contain a
CCL8-binding region that is transportable to another evasin.
Discussion
In this work, we have identified, using yeast surface display
approach, a novel evasin-like protein, P672_RHIPU (P672)
encoded in the salivary transcriptome of the tick R. pulchellus.
In the yeast surface display experiment, we found that only a
proportion of the clonal yeast population would bind CCL8.
This finding is likely due, in part, to the fact that only a propor-
tion of clonal yeast express surface display proteins (24), con-
sistent with our previous studies (14). As we were using yeast
surface display as a screening technique rather than a quantita-
tive measure of affinity, we explored the affinity of P672 for
CCL8 using purified recombinant proteins.
Alignment to other CC chemokine–binding evasins indi-
cates that P672 is an 8-Cys CKBP, with four disulfide bonds
predicted in its structure. P672 is most closely related to EVA4
with which it shares 36% identity. In particular, these are the
only two evasins identified to date that end immediately follow-
ing the terminal disulfide-forming Cys residue (ending on a
tryptophan) and have a tyrosine residue, instead of proline,
Figure 5. Functional neutralization of chemokine activity by P672. A and
B, neutralization of CCL3 (A)- and CCL8 (B)-induced THP-1 cell migration by
N-terminally taggedP672. The y axis shows cell count of THP-1 cellsmigrating
through to the bottom chamber in response to an EC80 dose of the indicated
chemokines. Data (three technical replicates) are shown asmean S.E. The x
axis shows P672 concentration (log10 molar). The IC50 indicated was esti-
matedby fitting an agonist response curvewith four parameters as described
(14). C, summary of N-terminally tagged P672 IC50 data (M, mean  S.E. of
three biological replicates analyzed as above) for chemokines that induce
THP-1 cell migration. The EC80 doses of the indicated chemokines were as
follows: CCL2, 0.52 nM; CCL3, 3.55 nM; CCL7, 7.18 nM; CCL3L1, 0.52 nM; and
CCL8, 5.75 nM.D, percentage ofmigration inhibition by a fixed concentration
(100 nM) of P672_CT (C-terminally tagged (open circles)) or P672_NT (N-termi-
nally tagged (filled squares)). The experiment was performed at an EC80 con-
centration of the chemokines indicated. Data (three technical and three bio-
logical replicates) were normalized to chemokine-alone control to account
for day today variation.Datawere analyzedwithone-wayanalysis of variance
and corrected for multiple comparisons with the Sidak method. ***, p 
0.001; ****, p 0.0001.
Hybrid evasins
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immediately following the first disulfide-forming Cys residue.
Notably this proline in EVA1 forms part of the binding surface
and is the residue that targets the conserved disulfide bond in
the target chemokine CCL3 (18). The significance of the sub-
stitution with tyrosine in P672 is yet unclear.
Like other evasins (14, 16, 25), P672 has several predictedN-
and O-glycosylation sites, which is consistent with its signifi-
cantly higher observed molecular weight and the presence of
several molecular-weight species on size exclusion chromatog-
raphy. PNGaseF treatment reduced themolecular weight, indi-
cating that there is significantN-glycosylation.We investigated
P672glycosylationusingmassspectrometryandfoundthatN-gly-
cosylation was indeed present and heterogeneous. Our data
indicate that deglycosylated P672 also binds CCL8, albeit with
reduced affinity. The mechanism for this action is unclear. Our
mass spectrometry data indicate that residue Asn-34 in P672,
which is part of the predicted binding surface, is glycosylated,
and upon deglycosylation is either converted to Asp or has a
single HexNAc sugar moiety attached. It is possible that these
changes may affect affinity, and studies are in progress to elu-
cidate themechanism. Although the affinity was reduced, it did
not hinder our studying the stoichiometry of the P672-CCL8
complex by native mass spectrometry.
We noted that P672 was obtained only in a single surface
display tag orientation in the yeast surface display screen, with
the tag positioned at the N terminus. This was unusual, as in
previous screens where other evasins were identified we typi-
cally obtained clones with tags in both the N- and C-terminal
positions (14). This observation is consistent with the marked
discrepancy in chemokine binding affinities, as measured by
biolayer interferometry, between N- and C-terminally
tagged versions of P672. The reduction in binding affinity
was consistent with the reduction in the ability of the protein
to neutralize the target chemokine in solution. An important
issue that we have not addressed here is the binding of
untagged P672 to chemokines. The StrepII-His tag is neces-
sary for rapid purification and, crucially, for binding to the
biolayer interferometry biosensor, allowing comparable
experiments for Kd determination. An exploration of the
properties of untagged P672 is necessary for future work and
will require the development of strategies for P672 purifica-
tion and quantifying binding affinities in the absence of a tag.
Another issue that we have not addressed is the possibility
that untagged or tagged P672 would bind non-chemokine
proteins or molecules. This is potentially important, as such
binding may mediate off-target effects if used therapeuti-
Figure 6. Analysis of the CCL8-P672 complex using native mass spectrometry. A, native MS of CCL8 homodimer. Inset shows sodium adducts of the
homodimer. B, native MS of partially deglycosylated N-terminally tagged P672. C, top panel and inset, native MS of P672-CCL8 complex. CCL8 and P672 were
mixed at a 1:1 ratio (final concentration of 2.5M) and incubated for 1 h at 4 °C. Peaks correspondingwith a glycosylated and sodiated CCL8-P672 heterodimer
(lowest intensity averagemass observed is 25,915.3 1.4 Da) are indicated (inset). Bottom panel, HCD fragmentation at 100 V of them/z 2956 isolated using a
100m/z isolationwindow. Peaks corresponding to sodiated CCL8 (top left inset) and a partially glycosylated P672 (top right inset) are indicated. In all sections of
this figure, the peaks are indicated as CCL8 (blue squares) or P672 (red squares). Monomers are indicated as a single square andhomo- or heterodimers as double
squares. The y axis indicates relative abundance, and the x axis indicates them/z (mass/charge) ratio.
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cally, and investigation of such binding is necessary in future
work.
Taken together these results indicate that the C-terminal tag
causes steric interference in the binding of P672 to certain
chemokines. The reduction in binding affinity seen with C-ter-
minal tagging may be explained by the close proximity of resi-
dues in the chemokine-binding surface of P672 with the C-ter-
minal residue of P672, which could lead to steric hindrance.
P672 was identified in a screen performed with the chemo-
kine CCL8 (also known as MCP-2) and in addition binds the
closely related chemokinesCCL2 (MCP-1) andCCL7 (MCP-3).
These three chemokines target the common receptor CCR2,
and CCL7 and CCL8 are thought to be partial agonists in com-
parison with CCL2 (26). CCR2 is a key regulator of monocyte
and macrophage migration (27), with potential roles in diverse
inflammatory disease including rheumatoid arthritis and
inflammatory bowel disease (1). Notably, P672 also binds to a
number of other CC chemokines. Some of these, such as CCL3
and CCL3L1, have functions in monocyte recruitment, and
P672 inhibits the function of these chemokines in monocyte
THP-1 cell migration assays. P672 also binds chemokines such
as CCL18, CCL14, CCL23, and CCL11 with 10 nM affinity.
These chemokines are involved also in lymphocyte (CCL18 (28)
and CCL14 (29)), monocyte (CCL14 (29) and CCL23 (30)), and
eosinophil (CCL11 (31) and CCL14 (29)) migration. As several
monocyte-recruiting chemokines are bound, a potential role of
P672 may be to block monocyte migration in the target hosts
of the tick R. pulchellus. Interestingly, we observed no binding
of P672 to CCL5 at chemokine concentrations below 300 nM.
CCL5 is a CCR1, CCR3, and CCR5 ligand (32) and is a major
chemoattractant for monocytes. The most likely explanation is
that ticks such as R. pulchellus have other evasins, such as
P467_RHIPU (14), that can bind CCL5 and thus complement
the action of P672.
Tick evasins appear to bind chemokines in a mutually exclu-
sive manner, with 8-Cys evasins binding exclusively to CC
chemokines and 6-Cys evasins such as EVA3 binding exclu-
sively to CXC chemokines. Furthermore, within each class,
evasins bind only subsets of CC or CXC chemokines. This has
been most clearly revealed by initial work showing that EVA4
binds to20CC chemokines, whereas EVA1 binds to only four
CC chemokines (13). P672, like EVA1, binds only toCCchemo-
kines, with some degree of overlap. For instance, both P672 and
EVA1 are able to bind to CCL3, CCL3L1, and CCL18. EVA1
binds to CCL4, which is not bound by P672. Conversely P672
binds CCL8, whereas EVA1 does not.
An interesting observation is that the IC50 of P672 for inhib-
iting CCL8-induced cell migration is close to the Kd of the
CCL8-P672 interaction. In this context, CCL8 binds as an ago-
nist to the chemokine receptors CCR1, CCR2, CCR3, and
CCR5 (32), and these receptors are known to act synergistically
to activate cellmigration (33). Based on this understanding, one
explanation for our observation is that titration of CCL8 by
P672 may ablate the synergistic effects that occur at a cellular
level following binding of CCL8 to its receptors. This could
have larger effects on cell migration than are predicted by the
Kd. An alternative explanation is that affinity measured by bio-
layer interferometry may be underestimated, as it involves
immobilization of the evasin, and this does not happen in the
cell migration assay.
To begin to explore how binding specificity in the context of
interactions between evasins and chemokines is created, we
Figure 7.Homologymodeling of the CCL8-P672 complex. This is a 3D structural model of P672 (orange and green) and CCL8 (gray and cyan) modeled as a
1:1 complex using the EVA1-CCL3 structure (ProteinData Bank ID 3FPU) as template andMODELLERwith default parameters after alignmentwith theMUSCLE
algorithm. The residues forming the binding surfaces predicted using Arpeggio (23) are indicated in green (P672) and cyan (CCL8). The N terminus residue of
P672 (Val-1) is indicated inblue and theC terminus residue (Trp-104) in red. TheNandC termini of CCL8 are indicated in yellow andmagenta, respectively.A and
D, P672-CCL8 complex shown in two orientations. B and E, P672-alone shown in two orientations. The position of residue Asn-34, which is in close proximity to
the C-terminal Trp-104, is indicated. C and F, CCL8 alone shown in two orientations.
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used native mass spectrometry. These studies showed that the
stoichiometry of the P672-CCL8 complex is 1:1, the same as the
previously reported EVA1-CCL3 structure. A homologymodel
of the P672-CCL8 complex based on the EVA1-CCL3 structure
and a deletion study suggested that the major CCL8-binding
region is located in the N-terminal 44 residues of P672. Trans-
ferring this region, which represents 42%of the P672 protein, to
EVA1 transported the CCL8 binding activity, confirming that
the determinants of CCL8 binding do indeed reside in the N
terminus. The reduced affinity of CCL8 binding by the hybrids
suggests that either other residues outside the transported
regions are needed for optimal binding to CCL8 or that the
folding of the transported residues is not optimal in the context
of the hybrid evasin. The loss of binding to other chemokines
(CCL3, CCL3L1, and CCL23) observed in the hybrids also sug-
gests that either other residues in P672 are needed for binding
to these chemokines or that the folding of the transported res-
idues is not optimal. The region identified as binding CCL8
represents 42% of P672; further experiments, beyond the
scope of this work, are in progress to narrow down the binding
region further. Taken together, these results suggest that
regions within a tick CKBP that act to confer chemokine bind-
ing can be identified by creating hybrid evasins.
In conclusion, the identification of several novel evasins that
bind distinctive subsets of CC chemokines provides the poten-
tial ability to match the chemokine-binding properties of an
evasin to the disease expression patterns of a chemokine, thus
generating biological tool compounds that target only disease-
relevant chemokines. A key challenge is to identify functional
regions within an evasin that could be used to engineer novel
CKBPs with altered properties, including increased binding to
certain chemokines and reduced binding to others. Analogous
approaches have been used, for instance to rationally engineer
antibodies with desired properties (34). In this study, by identi-
fying and functionally characterizing a novel tick evasin, we
have provided proof of concept that regions within evasins with
transportable properties can be identified and manipulated to
create non-natural hybrid proteins with altered characteristics.
Figure 8. Design and analysis of hybrid evasins. A, the construction of hybrid evasins is indicated in the diagram. B, binding affinities (Kd, M) of immobilized
P672, P672_EVA1 hybrids, and EVA1 to human CC-chemokines using biolayer interferometry. High-affinity binding is indicated in shades of green, medium
affinity in yellow, and low affinity in shades of orange. Chemokines are arranged by sequence similarity–based phylogeny. A dash (—) indicates that binding
wasnotdetectedat 300nMchemokine concentration.C, neutralizationofCCL8-inducedTHP-1monocyte cellmigrationbyP672(1_44)-EVA1(29_94). The y axis
shows cell count migrating through to the bottom chamber in response to an EC80 dose of CCL8. The Data (three technical replicates and three biological
replicates) are shown asmean S.E. The x axis shows P672(1_44)-EVA1(29_94) concentration (log10 molar). IC50 was estimated by fitting an agonist response
curve with four parameters as described (14).
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The further development of these approaches combined with
structural approaches and judicious application of steric hin-
drance through tag location may allow us to systematically
engineer novel evasins with the desired chemokine binding
activities.
Experimental procedures
Yeast surface display
Yeast surface display screening was performed as described
previously (14). Briefly, EBY100 yeast transformed with puta-
tive evasin library plasmids were induced with galactose to
drive expression of the surface-displayed protein, labeled with
biotinylated CCL8 (Almac) and streptavidin–Alexa Fluor 647,
and then sorted using FACS; cells non-specifically binding
streptavidin-AF647 were excluded using a sorting gate (Fig. 1).
Then sorted cells were regrown, and a second round of sorting
was performed followingwhich cells were plated at low dilution
to recover individual clones. Individual yeast clones were retested
by FACS to confirmCCL8 binding. Inserts fromplasmids isolated
from the individual clones were then PCR-amplified and
sequenced to identify the cloned evasin.
Plasmids
The P672 N-terminal and C-terminally tagged mammalian
expression plasmids were constructed in plasmid pHLSec (35)
using PCR and infusion cloning as described previously (14).
The purification tags were either an N-terminal His8-StrepII
protein purification tag (HHHHHHHHSAWSHPQFEKGG-
GGS) or aC-terminal StrepII-His8 protein purification tag (TGG-
GGGSGGGGSGGASAWSHPQFEKLEHHHHHHHH). Fol-
lowing signal peptide cleavage, an additional ETG sequence
predicted by SignalP 3.0 (36) was expected at the N terminus of
each peptide. P672-EVA1 hybrids and EVA1 expression plas-
mids weremade by PCR and infusion cloning into pHLSecwith
the C-terminal purification tag. The EVA1 plasmid used here
was based on GenBank sequence EZ406190.1, which encodes
EVA1 but with the variation K92N. The CCL8 expression plas-
mid was constructed by PCR amplification of a SUMO-CCL8
cassette and ligation-independent cloning into the vector
pNIC-BIO3 (a gift fromNicola Burgess-Brown (37)) to create a
HIS6-SUMO-CCL8 expression vector with a GSKGGYGLN-
DIFEAQKIEWHE C-terminal tag.
Protein sequence analysis
We used MUSCLE in Megalign Pro (DNAStar, version
12.3.1, DNAStar Inc.) to construct the CKBP and chemokine
sequence alignments and generate sequence similarity–based
phylogenetic trees. These were exported to FigTree (version
1.4.2, http://tree.bio.ed.ac.uk/software/figtree/).7 The amino
acid conservationwas plotted using the EMBOSS (38) program,
Plotcon (http://www.bioinformatics.nl/emboss-explorer/).7
Glycosylation sites were predicted using NetNGlyc1.0 (http://
www.cbs.dtu.dk/services/NetNGlyc/) and NetOGlyc4.0 (http://
www.cbs.dtu.dk/services/NetOGlyc/) (39).7 The molecular weight
and pI of proteins were calculated at ExPASy (http://web.
expasy.org/compute_pi/).7 We performed homology model-
ing using MODELLER (22) within PyMod 2.0 (40) with the
EVA1-CCL3 structure 3FPU (16) as template. Disulfide
bonds prediction was performed using the Protein Interac-
tion Calculator (41) and interchain interactions using the
Arpeggio server (23).
CKBP production
P672 in N- and C-terminally tagged versions were produced
as described previously (14). Briefly, culture supernatants from
transiently transfectedHEK293F cells were purified using nick-
el-charged IMAC Sepharose 6 Fast Flow resin (GE Healthcare)
followed by size exclusion chromatography. Fractions showing
absorption at 280 nm were analyzed by electrophoresis and
pooled for subsequent experiments.
Production of deglycosylated P672
The glycosylated protein precursor was prepared as
described above except that upon transfection of the cells kifu-
nensine was added to a final concentration of 7.5 g/ml. Puri-
fied glycosylated protein was concentrated, and the solution
was diluted 1:1 with 40 mM HEPES, 300 mM NaCl, and 1 mM
TCEP. PNGaseF (New England Biolabs) and Endo F1 (a gift
from C. Siebold, Division of Structural Biology (STRUBI), Uni-
versity of Oxford) was added to 2 mg of glycosylated P672 at a
ratio of 1:1000 and incubated overnight at 37 °C. Degylcosy-
lated protein was then separated from glycosylase enzymes by
size exclusion chromatography into 20 mM HEPES, 150 mM
NaCl, and 0.5 mM TCEP. We analyzed fractions showing
absorption at 280 nm by electrophoresis on a 12% SDS-PAGE,
which was stained with colloidal Coomassie.
CCL8 production
We expressed human CCL8 (residues Gln-24 to Pro-99) in
Escherichia coli RosettaGamiTM 2 (DE3) cells (Novagen). Cells
were grown at 37 °C overnight in LBmedium containing chlor-
amphenicol (25 g/ml), tetracycline (10 g/ml), and kanamy-
cin (50 g/ml). This culture was then diluted 1 in 30 into Ter-
rific Broth containing kanamycin (50 g/ml) and grown at
37 °C until an A600 of 0.8 was reached, at which point isopropyl
1-thio--D-galactopyranoside was added to a final concentra-
tion of 1 mM and the culture was incubated overnight at 18 °C.
Cells were pelleted by centrifugation (4000 g), and the result-
ing pellet was frozen and stored at 	80 °C. A 10-g pellet was
suspended in sonication buffer (20 mM NaH2PO4, 500 mM
NaCl, and 1 mM phenylmethylsulfonyl fluoride, pH 7.4) and
sonicated on ice to lyse the cells. The soluble and insoluble
fractionswere separated by centrifugation (31,000 g), and the
soluble fraction was loaded by gravity flow through nickel-
charged IMAC Sepharose 6 Fast Flow resin (GE Healthcare),
equilibrated with binding buffer (20 mM NaH2PO4, 500 mM
NaCl, pH 7.4), washed after binding with wash buffer (20 mM
NaH2PO4, 1 M NaCl, 20 mM imidazole, pH 7.4), and eluted in a
4-ml elution buffer (20 mM NaH2PO4, 500 mM NaCl, 500 mM
imidazole, pH 7.4) dropwise into a 20-ml cation exchange
buffer (20 mMNaH2PO4, 100 mMNaCl, pH 7.4). SUMO prote-
ase (Ubl-specific protease from Saccharomyces cerevisiae, a gift
from Dr. Ritika Sethi) was added (final concentration, 50
7 Please note that the JBC is not responsible for the long-term archiving and
maintenance of these sites or any other third party hosted site.
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g/ml) to the diluted elution and left overnight at 30 °C. The
cleaved proteinmixturewas loaded onto aHiTrapCapto S 1-ml
cation exchange column (GE Healthcare) pre-equilibrated in
cation exchange buffer (20 mM NaH2PO4, 100 mM NaCl, pH
7.4) using anAKTAstart. The columnwas thenwashedwith 5%
elution buffer (20 mM NaH2PO4, 1 M NaCl, pH 7.4) and the
protein eluted with a step elution of 50% elution buffer in 1-ml
fractions. The cleaved chemokine was purified to homogeneity
using size exclusion chromatography (Sephadex 16/600, GE
Healthcare) pre-equilibrated in a final buffer consisting of 20
mM HEPES, 500 mM NaCl, pH 7.4.
Biolayer interferometry
Biolayer interferometrywas performed on anOctetRed sys-
tem as described previously (14). Briefly, we performed cross-
binding against a panel of human chemokines at 300 nM
chemokine concentration. The excluded chemokines were
CCL25, CCL26, and CXCL16, which non-specifically bound to
the sensor, andCXCL17, CXCL4L1, andXCL2, whichwere not
available. We evaluated binding kinetics with chemokine con-
centrations ranging from 300 to 0.4 nM, using a non-interacting
reference protein to allow for nonspecific binding to the sensor.
We used ForteBio Data Analysis 9 software to process the data
and calculate association (kon), dissociation (koff), and affinity
(Kd) constants. Data with poor curve fits (R2  0.9) were
excluded. The dissociation half-life or target residence timewas
calculated as described (14, 42) from biolayer interferometry
off-rates (koff, s	1, as t1⁄2 0.693/(koff 60)).
THP-1 cell migration assays
THP-1 monocyte migration assays were performed as
described previously (14). Briefly, EC80 for each chemokine was
determined using a 96-Transwell migration plate (5 M pore
size, Corning), with chemokine doses (0–100 nM) in the bottom
chamber and THP-1 cells in the top chamber. Cells were
counted on an ATTUNE flow cytometer, and data were ana-
lyzed in GraphPad Prism fitting an agonist response curve with
four parameters. IC50 was determined using the above system.
An EC80 dose of the chemokine and 0–300 nM concentration
doses of the evasin were added to the bottom chamber and
incubated for 30 min at 37 °C before beginning the assay. IC50
was calculated in GraphPad Prism fitting an inhibitor response
curve with four parameters.
Determination of glycosylation sites
Aliquots of deglycosylated P672 were reduced with dithio-
threitol, alkylated using iodoacetamide, and digested with tryp-
sin or neutrophil elastase. Peptide aliquots from tryptic digests
(n  3) were analyzed by LC-MS/MS using an Easy-nLC 1000
coupled to an Orbitrap LTQ-XL (Thermo Fisher Scientific).
Peptides were desalted and concentrated by a C18 PepMap 100
trap (300 m 5 mm, 5 m particle size, 100 Å) for 5 min at a
flow rate of 20l/min and separated by a C18 Acclaim PepMap
RSLC column (75 m  250 mm, 2 m particle size, 100 Å)
using a linear gradient from 0 to 64% acetonitrile:H2O with
0.1% formic acid during 25min at a flow rate of 300 nl/min. For
samples run in the Orbitrap-LTQ-XL, precursor ions were
acquired at a mass resolution of 60,000 (m/z 400), and product
ions were acquired in the ion trap. The five most intense pre-
cursor ions of charge 2 were selected for fragmentation by
collision-induced dissociation (35 V), and dynamic exclusion
settings allowed a precursor to be selected up to three times in
a period of 30 s prior to being excluded for 60 s. The peptide
aliquot (n  1) from an elastase digest was analyzed using a Q
Exactive mass spectrometer coupled with a Dionex Ultimate
3000 UPLC as described previously (43). In brief, samples were
desalted online (PepMap C18, 300 m 5 mm, 5 m particle
size) for 1 min at a flow rate of 20 l/min and separated on an
Easy-nLC column (PepMap C18, 75 m 500 mm, 2 m par-
ticle size) over 60 min using a gradient of 2–35% acetonitrile in
5%DMSO, 0.1% formic acid at a flow rate of 250 nl/min. Survey
scans were acquired at a resolution of 70,000 (m/z 200); the 15
most abundant precursors of charge between 2 and 7 were
selected for HCD fragmentation (35 V), and dynamic exclusion
parameterswere set to select a precursor ion once prior to being
excluded for 60 s. Themass spectrometry proteomics data have
been deposited to the ProteomeXchange Consortium via the
PRIDE (44) partner repository with the dataset identifiers
PXD008025 and 10.6019/PXD008025.
Nativemass spectrometry
All samples were analyzed under native conditions using a
modifiedQ Exactivemass spectrometer (Thermo Fisher Scien-
tific) for high-mass range measurements. CCL8 was buffer-ex-
changed into 200mMammoniumacetate solution (pH6.5), and
deglycosylated P672 was buffer-exchanged into 50 mM ammo-
nium bicarbonate buffer (pH 6.5). The proteins were initially
analyzed separately using a capillary voltage of 1.2 KV and a
source temperature of 100 °C. In the case of deglycosylated
P672, 50 V of source-induced dissociation (SID) was added to
improve desolvation. The CCL8 protein sequence was charac-
terized from its monomers by increasing the source tempera-
ture to 200 °C and adding 30V of SID. The twomajor precursor
ions of CCL8 monomer,m/z 2257 andm/z 2821, were selected
with an isolationwindow of 5m/z and fragmented using several
acceleration voltages (80, 100, 150, and/or 180 V) of HCD. All
precursor and fragment ions were acquired using a mass reso-
lution of 60,000 with an average of 3 microscans and a signal-
to-noise threshold of 3. The Xtract algorithm fromXcalibur 3.0
software (Thermo Fisher Scientific) was used to determine the
decharged masses of the observed ions, which were then
inserted into ProSight Lite (http://prosightlite.northwestern.
edu)7 for identification of putative post-translational modifica-
tions within a precursor and product ion tolerance of 10 ppm.
Aliquots of CCL8 and deglycosylated P672 were mixed in a 1:1
ratio to reach a final concentration of 2.5 M and incubated for
1 h at 4 °C. The mixture was analyzed using the following
parameters: capillary voltage of 1.2 KV, source temperature of
130 °C, and 60 V of SID. The most intense charge state was
isolated with a 100m/z isolation window and dissociated using
100 V of HCD. In this case, precursor and dissociated products
were acquired using a mass resolution of 17,500 and 60,000,
respectively. Moreover, 2:1 and 3:1 ratios were also evaluated.
All measurements were done in triplicate.
Hybrid evasins
6144 J. Biol. Chem. (2018) 293(16) 6134–6146
 at N
ew
castle U
niversity on O
ctober 14, 2019
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
Statistical analyses
GraphPad Prism was used to calculate summary statistics
and tests of significance. The p value (probability of a type I
error) reported was adjusted for multiple comparisons. The
threshold () for a type I error was p 0.05.
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